CAJ | 학술논문

目的：观察氨磺必利治疗精神分裂症的临床疗效与安全性。方法将60例首发精神分裂症患者，随机分为氨磺必利组30例，利培酮组30例，疗程8周。采用阳性与阴性症状量表( PANSS )评定疗效，采用副反应量表( TESS )评定治疗中出现的不良反应。结果氨磺必利组的治疗总有效率为83.33%，利培酮组为80.00%，两组疗效差异无统计学意义( P＞0.05)；氨磺必利组的体重增加明显少于利培酮组( P<0.05)。结论氨磺必利与利培酮治疗精神分裂症疗效相当，且氨磺必利引起体重增加数例明显较少，值得临床推广。
목적：관찰안광필리치료정신분렬증적림상료효여안전성。방법장60례수발정신분렬증환자，수궤분위안광필리조30례，리배동조30례，료정8주。채용양성여음성증상량표( PANSS )평정료효，채용부반응량표( TESS )평정치료중출현적불량반응。결과안광필리조적치료총유효솔위83.33%，리배동조위80.00%，량조료효차이무통계학의의( P＞0.05)；안광필리조적체중증가명현소우리배동조( P<0.05)。결론안광필리여리배동치료정신분렬증료효상당，차안광필리인기체중증가수례명현교소，치득림상추엄。
Objective To observe the efficacy and safety of amisulpride in the treatment of schizophrenia. Methods 60 cases of first episode schizophrenia were randomly divided into the amisulpride group and the risperidone group with 30 cases in each group and treated for 8 weeks. The positive and negative symptom scale ( PANSS ) was adopted to evaluate the efficacy and the treatment emergent symptoms effect scale ( TESS ) was used to evaluate the adverse reactions. Results The total effective rate after treatment in the amisul-pride group was 83. 33%, while which in the risperidone group was 80. 00% without statistically significant difference between the two groups ( P > 0. 05 ) . The weight gain of the amisulpride group was significantly less than that of the rispefidone group ( P < 0. 05 ) . Conclusion Amisulpride and rispefidone have a similar therapeutic effect, but the case number of weight gain caused by amisulpride is significantly decreased, amisulpride deserves to be clinically popularized.